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ABSTRACT: Hospitalized patients with hepatic insuffi-
ciency often suffer from severe catabolic states and are in
urgent need of nutrition support during their acute ill-
ness. Protein intolerance, however, remains a significant
problem with respect to the provision of adequate nutri-
tion, either enterally or parenterally. The following report
is an anecdotal series of 63 consecutive patients in a large
urban hospital treated prospectively with nutrition sup-
port using a prototype high branched-chain amino acid
solution (FO80) given by technique of total parenteral
nutrition (TPN) by the subclavian or internal jugular
route with hypertonic dextrose. Sixty-three patients, of
which 42 had chronic liver disease (cirrhosis) with acute
decompensation and 17 with acute hepatic injury and four
with hepatorenal syndrome, are the subject of this report.
All required IV nutrition support and were either intoler-
ant to commercially available parenteral nutrition solu-
tions or were in hepatic encephalopathy at the time they
were initially seen. The cirrhotic patients had been hospi-
talized for a mean of 14.5  1.9 days before therapy, had
a mean bilirubin of 13 mg/100 mL, and had been in coma
for 4.8  0.7 days despite standard therapy. Patients with
acute hepatitis had been in the hospital for 16.2  4.1 day
before therapy, had a mean bilirubin of 25 mg/100 mL,
and had been in coma 5.2  1.6 days before therapy.
Routine tests of liver function, blood chemistries, amino
acids, EEGs, and complex neurologic testing including
Reitan trailmaking tests were used in the evaluation of
these patients. Up to 120 g of synthetic amino acid
solution with hypertonic dextrose was tolerated in these
patients with improvement noted in encephalopathy of at
least one grade in 87% of the patients with cirrhosis and
75% of the patients with hepatitis. Nitrogen balance was
achieved when 75 to 80 g of synthetic amino acids were
administered. Survival was 45% in the cirrhotic group and
47% in the acute hepatitis group. Encephalopathy
appeared to correlate with individual amino acids differ-
entially in the various groups and with the ratio between
the aromatic and the branched-chain amino acids. Ammo-
nia did not correlate with either the degree of encephalop-
athy or improvement therefrom. In 24 patients therapy for
hepatic encephalopathy was limited to infusion of the
branched-chain enriched amino acid solution only, with
wake-up in 66% of this group. The results strongly suggest
that in protein intolerant patients requiring nutrition
support, infusion with branched-chain enriched amino
acid solutions is well tolerated with either no worsening of
or improvement in hepatic encephalopathy coincident
with the achievement of nitrogen equilibrium and ade-
quate nutrition support. (Freund H, Dienstag J, Lehrich J,
et al. Infusion of branched-chain amino acid solution in
patients with hepatic encephalopathy. Ann Surg 196:209–
220, 1982)
Hepatic Encephalopathy
Hepatic encephalopathy (HE) is a neuropsychiat-
ric disorder that develops in patients with acute and
chronic liver disease. Patients with HE may show
alterations in consciousness, psychomotor, cogni-
tive, and behavioral functions. Based on the level of
alteration of these functions, the severity of HE is
classified in clinical grades ranging from I–IV, with
grade I associated with mild cognitive dysfunction to
grade IV as the most advanced stage associated with
coma.1 Several theories have been proposed to
explain the pathogenesis of HE, but none of these
theories has been clearly established. The theories
include -amino butyric acid neuroinhibition; amino
acid imbalance; ammonia, sulfur-containing amino
acid (mercaptans), short- and medium-chain fatty
acid, and aromatic amino acid (AAA) neurotoxicity;
and zinc deficiency. The treatment of HE consists
primarily of identifying and correcting the precipi-
tating factors and lowering ammonia levels. Lower-
ing serum ammonia levels is accomplished by the
administration of laxatives (eg, lactulose) to reduce
ammonia absorption from the intestines, oral anti-
biotics (eg, neomycin) to reduce ammonia production
by colonic bacteria, and a low-protein diet to mini-
mize ammonia production and avoid excess AAA
intake.1–2 The use of branched-chain amino acids
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(BCAA) in the treatment of HE, however, remains a
subject of controversy. This review focuses on the
role of IV BCAA-enriched formulas in the treatment
of acute HE. The role of oral BCAA formulas in the
treatment and prevention of chronic HE has been
thoroughly reviewed elsewhere.3
Amino Acid Imbalance in Patients With
Hepatic Failure
Malnutrition is a common finding in patients with
liver disease and correlates with increased morbid-
ity and mortality.4 The prevalence of protein-energy
malnutrition has been reported in 27% to 87% of
patients with liver cirrhosis.5 Hypercatabolism dur-
ing liver disease, along with dietary protein restric-
tion, can lead to protein malnutrition and negative
nitrogen balance. Regardless of the patient’s nutri-
tional status, amino acid imbalance is a common
finding in patients with hepatic failure. Patients
with hepatic failure show increased plasma concen-
trations of AAAs (phenylalanine, tyrosine, trypto-
phan) and methionine and decreased plasma con-
centrations of BCAAs (leucine, isoleucine, valine).6
This observation has led to the hypothesis that
amino acid imbalance may contribute to HE.
The low plasma concentrations of BCAAs in
patients with hepatic failure could be the result of
increased degradation of BCAAs caused by skeletal
muscle breakdown during catabolism, reduced pro-
tein intake, or as a possible result of hyperammone-
mia-induced increased BCAA use. On the other
hand, the increase in plasma AAA concentrations is
due in part to decreased liver function, because the
liver is the primary site for AAA metabolism.7 It is
hypothesized that alterations in plasma amino acid
concentrations would also affect the amino acid
levels in the brain. In patients with hepatic failure,
the decreased plasma molar BCAA:AAA ratio could
favor the transport of AAAs into the brain as they
compete for the same carrier across the blood-brain
barrier. This transport is further facilitated by the
increased blood-brain barrier permeability as a con-
sequence of hepatic failure, which leads to the accu-
mulation of AAAs in the central nervous system.
Based on the theory of “false neurotransmitters,”
excess tyrosine in the brain is converted to octop-
amine, and phenylalanine is converted to phenyleth-
anolamine.8 The newly formed octopamine and phe-
nylethanolamine have been referred to as “false
neurotransmitters.” The way “false neurotransmit-
ters” may precipitate HE is by either replacing the
normal neurotransmitters (eg, dopamine and nor-
epinephrine) at central nerve endings or by compet-
ing for normal synaptic transmission.1,9 If this the-
ory holds true, then changes in the plasma BCAA:
AAA ratio would be expected to correlate with the
degree of HE.
As such, Fischer et al10 first used the plasma
molar ratio of BCAA:AAA ratio (valine  leucine 
isoleucine:phenylalanine  tyrosine) as a marker of
the degree of HE. A ratio of 3 to 3.5:1 is considered
normal, whereas a ratio 1 correlates with HE.
Therefore, if HE correlates with abnormalities in
plasma amino acid concentrations, then normaliza-
tion of plasma amino acids with an exogenous source
of a high-BCAA, low-AAA formula might improve
HE while allowing adequate protein intake to
achieve nitrogen balance.7 Because BCAAs are
essential amino acids, they cannot be synthesized in
the body and thus need to be supplemented from an
exogenous source. As such, using a BCAA-enriched
formula is based on the hypothesis of amino acid
imbalance, with the aim of correcting the plasma
BCAA:AAA ratio and possibly treating or prevent-
ing HE.
IV BCAAs and HE
The original “hypothesis” of Fischer and Baldes-
sarini11 provided the initial concept linking the
formation of “false neurotransmitters” and amino
acid imbalance to HE in patients with liver disease.
Since then, clinical studies have emerged to evalu-
ate the role of IV and oral BCAA formulas in
patients with acute and chronic HE. These studies
have primarily focused on three treatment out-
comes: (1) improvement of HE; (2) improvement of
the nutritional status; and (3) effect on the survival
of patients with liver disease.12
The paper by Freund et al,13 published in 1982,
explored the effects of IV BCAAs on recovery from
HE, amino acid balance, and nutritional status of
patients with liver disease. This was a prospective
uncontrolled trial of 63 patients with liver disease
who had HE (grade  I) or had intolerance to
conventional amino acid formulas, and who required
parenteral nutrition (PN). Patients were divided
into three groups: group I included 42 patients with
chronic liver disease and cirrhosis with acute HE or
coma; group II included 17 patients with acute
hepatitis; and group III included 4 patients with
hepatorenal syndrome. All patients received a high-
BCAA, low-AAA solution as part of their dextrose-
containing PN regimen. PN provided a maximum of
120 g/d of amino acids and 3000 kcal/d. BCAAs
provided 35% of the total amino acids in the special-
ized formula. Of the 63 patients included in the
study, 24 patients did not receive any other treat-
ments for HE (ie, neomycin, lactulose, or cathartics)
other than BCAAs. The mean duration of patient
treatment was 13  1 days in group I, 13.2  3.8
days in group II, and 17.2  11.3 days in group III.
Routine testing included blood chemistries, liver
function tests, plasma amino acids and ammonia
levels, and neurologic testing. Results of this study
showed a significant correlation between plasma
BCAA:AAA ratio and the degree of HE (group I: p 
.02; group II: p  .002). After treatment with the
specialized amino acid formula, there was a signifi-
cant increase from baseline in the BCAA:AAA ratio
in group I patients (p .001), but the increase in the
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ratio in group II patients was not statistically sig-
nificant. Nitrogen balance significantly correlated
with the BCAA:AAA ratio and the amount of nitro-
gen intake (group I: p  .001; group II: p  .01). The
amounts of amino acids delivered to patients ranged
from 60 to 120 g/d and were well tolerated. Nitrogen
balance was achieved with amino acid intake of 75 to
80 g/d. There was also a significant linear correla-
tion between daily BCAA intake and nitrogen bal-
ance. After 3 days of treatment, HE improved in 56%
and 25% in group I and II, respectively. Survival
rate was similar in group I (45%) and group II (47%),
but was lower in group III (25%). For the 24 patients
who received the BCAAs and dextrose only without
other treatment modality, 66% of them had improve-
ment in HE with a 50% survival rate. The study
concluded that a high-BCAA, low-AAA IV formula
corrects plasma amino acid imbalances, achieves
nitrogen balance equilibrium, and may improve
HE.13 However, limitations to this study are several
and include the lack of randomization, absence of a
control group, and absence of blinding to treatment.
These limitations prohibit drawing firm conclusions
as to the role of BCAAs in patients with severe liver
disease. Thus, prospective, randomized, double-
blind studies were still needed to confirm the results
of this study.
Since the publication of the study by Freund et
al,13 several clinical studies evaluated the role of IV
BCAAs in the treatment of acute HE.14–20 A meta-
analysis21 and a clinical critique of studies22 were
published at about the same time in 1989, but
reached opposing conclusions as to the role of
BCAAs in patients with liver disease. The 2 papers
further raised the debate about the role of BCAAs
and the authors took sides in defending their points.
Naylor et al21 conducted a meta-analysis that
included 9 clinical studies14,15,18,23–28 to evaluate
the role of IV BCAAs on mental recovery and sur-
vival of patients with acute HE. The meta-analysis
included 6 completed randomized controlled stud-
ies,14,15,18,23,27,28 2 randomized controlled studies in
abstract format,25,26 and 1 study that did not have a
randomized controlled design.24 Using different
ways of data aggregation, the authors concluded
that IV BCAA formulas significantly improve recov-
ery from HE and perhaps reduce mortality. The
authors acknowledged some of the study limitations
and cautioned that IV BCAAs could not be recom-
mended for routine use over conventional therapies,
and that there is a need for larger randomized,
controlled studies with longer follow-up times.21
Nonetheless, critics of the meta-analysis were
numerous, underscoring the validity of the positive
conclusions derived from the meta-analysis. The
cited limitations addressed the heterogeneity of
studies included in the meta-analysis, the type of
control therapy, the wide variation in patient selec-
tion, the differences in duration of therapy, the
amounts of BCAAs used, and the differences in
study endpoints.29 Other critics addressed the meth-
ods of literature retrieval and combination of data,
discrepancies in data abstraction, the inclusion of
data form abstracts and preliminary reports, and
the method used for data analysis.30–34
Eriksson and Conn critically reviewed and ana-
lyzed the strengths and weaknesses of studies that
addressed the role of BCAAs in HE. The 7 ran-
domized, controlled studies included in their re-
view14–19,35 were not all the same as those included
in the meta-analysis by Naylor et al.21 Eriksson and
Conn grouped the studies into different categories
relative to the role of BCAA in acute HE, chronic
HE, subclinical HE, and their effect on nitrogen
metabolism. As stated in the review,22 data from the
2 studies that compared BCAAs with glucose15,35
and from the 1 study that compared BCAAs with
standard amino acids17 showed no statistically sig-
nificant difference on HE and mortality between the
treatment and control groups. None of the 4 studies
that compared BCAAs with either lactulose14,16 or
neomycin18,19 reported significant differences in
improvement of HE or mortality. As such, the
reviewers concluded that “BCAA therapy, whether
pure or combined with other amino acids, irrespec-
tive of the amount administered, does not appear to
affect significantly the outcome of patients with
acute HE.”22 Even if some studies have shown that
BCAAs may be at least as effective as conventional
therapy, the positive outcome of BCAA therapy has
not been replicated in other studies. Also, BCAAs
have not shown to be superior to standard amino
acids in improving acute HE.
Conclusion
Over 30 years of research have passed and the
“false neurotransmitter” hypothesis has not been
clearly proven, nor has the debate about the role of
BCAAs in HE been settled. The limitations of the
available studies addressing the role of BCAAs
include differences in the types, amounts, and com-
position of BCAAs, and variations in outcome mea-
surements and quality of study designs. Although
some investigators’ personal experience favors the
use of BCAAs, the lack of convincing scientific evi-
dence supporting the effectiveness of BCAA formu-
las has limited their routine use. Currently, 1 spe-
cialized IV amino acid formula (HepatAmine, B.
Braun, Bethlehem, PA) is marketed in the United
States for patients with HE. This specialized for-
mula contains no tyrosine and provides BCAA at
about 35% of total amino acids. As for the role of oral
BCAAs in chronic HE, recommendations are to limit
their use only to patients who are intolerant to
dietary proteins, especially patients with advanced
cirrhosis.3,22 A consensus review in 1997 by the
European Society of Parenteral and Enteral Nutri-
tion (E.S.P.E.N) concluded that even if IV BCAAs
may have an effect on the patient’s mental state,
although the improvement may not necessarily be
the result of nutrition alone, they have no effect on
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patient survival. However, the consensus recom-
mended the use of IV BCAA formulas in patients
receiving PN with advanced grade III–IV HE.36 The
Practice Guidelines published by the American
Society for Parenteral and Enteral Nutrition
(A.S.P.E.N.) state that “there is no consensus con-
cerning the use of BCAA-enriched supplements in
the treatment of acute hepatic encephalopathy,” and
that the “use of BCAA-enriched diets or specialized
nutrition support formulas is only indicated in
chronic encephalopathy unresponsive to pharmaco-
therapy.”37
In summary, BCAA-enriched formulas have not
shown significant advantage over standard amino
acid formulas and are more costly. Other precipitat-
ing factors of HE should be ruled out before consid-
ering the patient protein intolerant. During the
acute phase of HE, temporary protein restriction to
0.6 to 0.8 g/kg per day is recommended. Except in
the minority of protein-intolerant patients, normal
protein intake can be resumed in most cirrhotic
patients after the resolution of the acute episode of
HE to avoid protein malnutrition.
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